Show Summary Details
Page of

Obsessive–compulsive disorder 

Obsessive–compulsive disorder
Chapter:
Obsessive–compulsive disorder
Author(s):

Joseph Zohar

, Leah Fostick

, and Elizabeth Juven-Wetzler

DOI:
10.1093/med/9780199696758.003.0100
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 25 August 2019

The efficacy of the SRIs for OCD, together with the lack of efficacy of adrenergic antidepressants, has suggested that serotonin is involved in the pathophysiology of OCD. This relationship was validated by research on serotonergic markers in OCD and by the challenge paradigm. Which type of serotonergic receptor is involved in the pathogenesis and/or the mechanism of action of anti-obsessional drugs, is still unclear. However, the possible role of 5HT1B has emerged. Further studies are crucial for elucidating the role of serotonin and other neurotransmitters (i.e. dopamine) in the pathophysiology and management of OCD.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.